An In Vivo Predictive Dissolution Methodology (iPD Methodology) with a BCS Class IIb Drug Can Predict the In Vivo Bioequivalence Results: Etoricoxib Products

• Главные авторы: Isabel Gonzalez-Alvarez (Автор), Marival Bermejo (Автор), Yasuhiro Tsume (Автор), Alejandro Ruiz-Picazo (Автор), Marta Gonzalez-Alvarez (Автор), Bart Hens (Автор), Alfredo Garcia-Arieta (Автор), Greg E. Amidon (Автор), Gordon L. Amidon (Автор)
• Формат: ‌
• Опубликовано: MDPI AG, 2021-04-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

The purpose of this study was to predict in vivo performance of three oral products of Etoricoxib (<i>Arcoxia</i>^® as reference and two generic formulations in development) by conducting in vivo predictive dissolution with GIS (Gastro Intestinal Simulator) and comp...